Results 11 to 20 of about 216,656 (337)

Antiviral anticoagulation [PDF]

Research and Practice in Thrombosis and Haemostasis, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel envelope virus that causes coronavirus disease 2019 (COVID-19). Hallmarks of COVID-19 are a puzzling form of thrombophilia that has elevated D-dimer but only modest effects on other parameters of coagulopathy.
Pryzdial, Edward L. G., Sutherland, Michael R., Lin, Bryan H., Horwitz, Marc   +3 more
openaire   +3 more sources

Why INR is outside the therapeutic range in patients with acuteischemic stroke and atrial fibrillation [PDF]

Journal of Research in Clinical Medicine, 2022
Introduction: Warfarin is still the primary drug used to prevent vascular events in patientswith atrial fibrillation (AF), especially in low-income countries. Therapeutic failure and non-adherenceare common causes of recurrent embolic events.
Elyar Sadeghi Hokmabadi, Sheida Shaafi, Yalda Sadeghpour, Reza Deljavan, Javad Jalili, Morteza Ghojazadeh, Elyar Alizade Najmi, Saeid Charsouei, Mehdi Farhoudi   +8 more
doaj   +1 more source

Necrotizing Pancreatitis: To Anticoagulate or Not to Anticoagulate?

Cureus, 2022
Necrotizing pancreatitis is an inflammatory process that poses a strong risk of systemic venous thromboembolism. However, it is often challenging to opt for systemic anticoagulation since the disease is also associated with an increased risk of hemorrhage.
Abi-Saleh, Simon P, Miller, Ethan A, Magge, Anil, Perez, Mario   +3 more
openaire   +2 more sources

Impact of Alteplase on Mortality in Critically Ill Patients with COVID-19 and Pulmonary Embolism

Viruses, 2023
COVID-19 is an independent risk factor for pulmonary embolism (PE). Little is known about alteplase therapy in this patient group. A retrospective study analyzed 74 patients with PE and acute respiratory distress syndrome (ARDS) due to COVID-19 who were ...
Oleksandr Valentynovych Oliynyk, Marta Rorat, Serhij Oleksandrovych Solyarik, Vitaliy Andrijovych Lukianchuk, Serhij Oleksandrovych Dubrov, Vitaliy Hrygorovych Guryanov, Yanina Volodymyrivna Oliynyk, Svitlana Mykolaivna Yaroslavskaya, Roman Szalast, Wojciech Barg   +9 more
doaj   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Anticoagulants and Osteoporosis [PDF]

International Journal of Molecular Sciences, 2019
Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis.
Signorelli S. S., Scuto S., Marino E., Giusti M., Xourafa A., Gaudio A.   +5 more
openaire   +3 more sources

Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]

, 2013
OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N, Green, L, Hull, SA, MacCallum, PK, Mathur, R, Morris, JK, Saja, K   +6 more
core   +3 more sources

Anticoagulation in the Elderly [PDF]

Pharmaceuticals, 2010
Management of anticoagulation in elderly patients represents a particularly challenging issue. Indeed, this patient population is at high thromboembolic risk, but also at high hemorrhagic risk. Assessment of the benefit-risk balance of anticoagulation is the key point when decisions are made about introducing and/or continuing such treatments in the ...
Robert-Ebadi, Helia, Righini, Marc Philip   +1 more
openaire   +3 more sources

Anticoagulants [PDF]

Journal of Pharmacy and Pharmacology, 1949
Abstract The processes that underly the clotting of blood are still far from adequately understood, in spite of the many facts uncovered by generations of patient investigators. The classical scheme associated with the name of Morawitz1, although neither complete nor universally accepted, is still useful as a summary of the main events ...
openaire   +3 more sources

Comparative Evaluation of Efficacy, Safety and Haemostatic Parameters of Enoxaparin and Fondaparinux in Unstable Coronary Artery Disease [PDF]

Journal of Clinical and Diagnostic Research, 2014
Aim: To compare the safety and efficacy of Enoxaparin (EX) and Fondaparinux (FD) in patients with Unstable Coronary Artery Disease (UCAD). Materials and Methods: A prospective, open label, randomized comparative study was designed to study the ...
Sanjay Shah, Vijay Khajuria, Vishal R. Tandon, Zahid H.Gillani, Mohan Lal   +4 more
doaj   +1 more source